sion; induction therapy; renal transplantation; triple therapy Background. Sensitized kidney allograft recipients require special management to improve their outcome. One strategy is heavy immunosuppression with antilymphocyte antibodies. Controversy continues about
Pathological features were divided into two categories, cellubest graft survival rate was achieved with the early lar rejection and vascular rejection. The Banff classification introduction of cyclosporin, even when compared with was only applied retrospectively at the end of the study.
sequential induction with antilymphocyte antibodies.
When rejection was clinically suspected but without histoWe wanted to analyse the advantage that an induction logical confirmation, a presumptive rejection episode was therapy could add to cyclosporin usage in sensitized considered. Secondary criteria were early side effects, compatients. We therefore conducted a PRA-stratified, plications, graft survival and graft function. Early side effects randomized prospective study to compare induction were considered within 3 weeks after transplantation, with with and without ATG in sensitized cyclosporin-treated particular attention to fever and haematological tolerance. kidney recipients.
A leukocyte count below 3 g/l was considered as leucopenia, a platelet count below 150 g/l as thrombocytopenia. Delayed graft function was defined as the need for dialysis within the Subjects and methods first week. Every event occurring within 3 months was considered as a complication. All gammopathies and cancers were recorded. We considered as cytomegalovirus (CMV )
Patient population
infections asymptomatic serological conversions and clinical CMV diseases. Graft survival was calculated according to Conducted from 1991 to 1995, this study included all sensitKaplan-Meier. Graft function was assessed by 1 year serum ized patients receiving either a first or a second graft, from creatinine and inulin clearance. a cadaveric or a living donor, even in the case of a historical or current positive B-cell crossmatch. Third grafts and grafts performed against a positive historical T-cell crossmatch
Results
were excluded. Sensitization was defined by the presence in the patient's serum of lymphocytotoxic antibodies recognizing at least 5% of a panel of 24-30 whole lymphocytes from Demography different donors. The randomization was stratified on Forty two patients were given a triple therapy without maximum PRA in order to obtain a well-balanced distribution, whatever the level of sensitization. We defined the ATG and 47 received ATG. The actual ATG dose was following five classes: 5%<PRA∏20%, 20%<PRA∏40%, 0.79±0.19 mg/kg/day (0.5-1.3). On comparison, there 40%<PRA∏60%, 60%<PRA∏80% and 80%<PRA∏ was no difference between the two groups with regard 100%. This last class refers to the classic definition of to pre-therapeutic conditions and, in particular, hypersensitized patients.
immunological status ( Table 1) . In both groups, the numbers of second grafts, mean PRA, human leukoImmunosuppressive protocols cyte antigen (HLA) mismatch and positive B crossmatches were similar. The patients were equally The triple therapy consisted of cyclosporin, azathioprine and distributed with regard to PRA stratification, with 12 steroids. Cyclosporine (SandimmumB, Sandoz) was intro-and 14 patients with 5%<PRA∏20%, 14 and 12 duced before graft implantation, at an oral equivalent of patients with 20%<PRA∏40%, five and six patients 14 mg/kg/day dose, tapered every second day to obtain an with 40%<PRA∏60%, four and five patients with 8 mg/kg/day dose at the end of the first week. Further 60%<PRA∏80% and finally seven and 10 patients adjustments were made carefully according to daily trough with 80%<PRA∏100% respectively. levels, with a 100-300 mg/l target range. Azathioprine was given at 2 mg/kg/day and prednisolone at 30 mg/day. ATG induction comprised the same therapy with cyclosporin and Acute rejection episodes prednisolone, plus a 10 day ATG course (ThymoglobulinB, IMTIX Pasteur-Mérieux-Connaught, Lyon, France), given Presumptive rejection episodes numbered 30 (71%) in at a 1.25 mg/kg/day as the starting dose. The number of the triple therapy group and 25 (53%) in the ATG peripheral CD2 and CD3 lymphocytes was monitored three times a week to adjust ATG doses. Azathioprine was intro- dysfunction which was not explained eventually led to a biopsy. Rejection episodes were confirmed based on the results of a percutaneous 18-gauge needle biopsy. The P-value was not significant in all cases.
group (P=0.008). There was also a significant differ-simplex virus infections (4 vs 4%), serious bacterial infections (12 vs 13%), urinary tract infections (26 vs ence in the incidence of biopsy-proven acute rejections: 27 (64%) in the triple therapy group and 18 (38%) in 24%), gammopathies (12 vs 8%) and de novo cancers (7 vs 2%). Delayed graft function, which may dispose the ATG group (P=0.02). The mean onset of the first acute rejection episode was 8±8 days in the triple to rejection, occurred in 33% of the patients in the triple therapy group and in 28% of the patients in the therapy group vs 24±45 days in the ATG group (P= 0.02). The median onset was 8 days (4-31) and 5 days ATG group (not significant; NS).
The median duration of follow-up was 25 months, (1-182) respectively. The percentage of biopsies with vascular lesions was similar in the two groups (33 vs ranging from 1 to 52 months. Graft survival in the triple therapy group and in the ATG group was 81 vs 39%). Rejection episodes were also analysed according to PRA (Figure 1) . The advantage of ATG induction 94% at 6 months and 76 vs 89% at 12 months respectively (Figure 2 ) (Breslow: P=0.06, Mantel-Cox: P= was somewhat different according to the level of sensitization and, surprisingly, highly sensitized patients did 0.04). However, the causes of graft lost were not equally distributed. Non-immunological graft failures not exhibit any greater benefit from ATG induction. When patients were grouped on the basis of the lowest occurred mainly in the triple therapy group (6/12), with two surgical failures, one recurrent glomerulo-PRA, a clear reduction in rejection episodes appeared in each group ( Table 2) .
nephritis and three deaths, and were less frequent in the ATG group (1/5) with one venous thrombosis. Acute or chronic rejections represented six out of the Secondary end points 12 graft failures in the triple therapy group (50%) and The use of ATG induced more leucopenia (43 vs 17%, four out of the five graft failures in the ATG group P=0.007) and thrombocytopenia (32 vs 17%, P= (80%). When the graft survival calculation was cen-0.008). Apart from these two early side effects, adverse sored for non-immunological graft failures, we found events were similar in the two groups. We did not note a much smaller difference, but still a trend in favour any difference between the triple therapy group and of ATG, with 84 and 91% 1-year graft survival respectthe ATG group with regard to fever (26 vs 36%), CMV ively (NS ). infection (40 vs 59%), Epstein-Barr virus and herpes Finally, we compared graft function at 1 year. Serum creatinine was 168±77 mmol/l in the triple therapy group vs 146±56 mmol/l in the ATG group (NS), but inulin clearance was 37±15 ml/mn vs 49±18 ml/mn respectively (P=0.005).
Level of sensitization and positive crossmatches
We looked for a possible effect of the level of sensitization on the occurrence of an acute rejection episode as well as on graft survival. Rejection occurred in 50% of patients with 5%<PRA∏20%, in 77% of patients with 20%<PRA∏40%, in 73% of patients with 40%< PRA∏60%, in 56% of patients with 60%<PRA∏80% post-transplantation. One should be aware of these late rejections which could jeopardize the results and in 53% of patients with 80%<PRA∏100% (NS). We found similarly that graft survival was not affected obtained with ATG.
Surprisingly, treatment with ATG did not induce by the level of sensitization (data not shown). The consequences of having a positive crossmatch were many more early side effects or adverse reactions, but we must point out that rather low doses were used. also examined. Fifty percent of patients who had either a positive or a negative crossmatch developed an acute There is a strong relationship between side effects and the duration of treatment [26 ] . Careful monitoring of rejection. One year graft survival was 81% in patients with a negative crossmatch and 88% in patients with T cells could also reduce the incidence of infections [27] . It is therefore logical to use a potent but carefully a positive crossmatch (NS).
adjusted and short-lasting induction protocol.
The most striking result is that ATG induction was
Discussion
of benefit to all the sensitized patients and not only the highly sensitized patients. The highly sensitized patients exhibited a mild reduction in acute rejection Quadruple immunosuppression regimens and sequential antilymphocyte antibody regimens have achieved episodes; they remain very difficult patients to treat.
Usually, a lot of attention is paid to hypersensitized good results in sensitized patients [14] [15] [16] [17] . Nevertheless, conflicting results have been published patients, whereas patients with lower levels of sensitization are often excluded from joint programmes and [18] [19] [20] [21] , and to date we still lack formal proof of the advantage of prophylactic antilymphocyte antibodies clinical studies. It has been reported that sensitized patients with a PRA <50% had a graft survival rate for sensitized patients. Indeed, these regimens may also increase the risk of infections and neoplasia [19] . which compared favourably with those of more highly sensitized patients [3, 28] , but little is known about the Moreover, since cyclosporin has been used, the effect of sensitization on acute rejection and graft survival clinical management of these patients. Our results support the systematic use of an induction therapy in may have been weakened [22] [23] [24] . At a time when promising new immunosuppressants are coming on to all sensitized patients.
In conclusion, a prophylactic 10-day course of lowthe market, it may be useful to assess the results we can achieve with our existing immunosuppressants and dose ATG, given to cyclosporin-treated sensitized kidney recipients, decreased the incidence of acute standard strategies.
The choice between anti-CD3 and antilymphocyte rejection episodes, increased graft survival and improved graft function. All sensitized patients, whatantibodies remains difficult. In a study carried out in sensitized patients, Vela compared ALG with OKT3 ever their PRA level, benefited from this ATG induction therapy. [12] and concluded that they were equally effective but that side effects were less frequent with ALG. Although ATG is more recent than ALG, it has been recognized References as a potent immunosuppressive agent [25] .
We found that induction therapy with ATG in would not have avoided these graft losses in that group 
